Researchers at Rockefeller University have reported promising findings from an early-stage clinical trial of a newly redesigned cancer immunotherapy delivered directly into tumors.

Encouraging Early Clinical Trial Results

In the small study, half of the 12 participants experienced tumor shrinkage, while two patients achieved complete remission, according to results published in Cancer Cell.

These early outcomes suggest that the treatment may offer a powerful new approach to fighting cancer, especially in advanced cases.

Localized Treatment with Systemic Impact

One of the most remarkable aspects of this therapy is that its effects were not limited to the injected tumors. In several cases, tumors located in other parts of the body also shrank or disappeared, indicating a strong whole-body immune response.

This unexpected outcome highlights the therapy’s potential to treat metastatic cancers more effectively.

How the CD40-Based Therapy Works

The treatment is based on CD40-targeting drugs, which stimulate the immune system to recognize and attack cancer cells. Traditionally, these drugs are administered through the bloodstream, often leading to widespread side effects such as inflammation and liver damage.

To improve safety, researchers modified the drug—called 2141-V11—and changed how it is delivered.

Direct Tumor Injection Reduces Side Effects

Instead of intravenous infusion, the therapy is injected directly into tumors. This targeted approach significantly reduces systemic exposure and minimizes side effects.

Researchers reported that patients experienced only mild toxicity, making the treatment more tolerable compared to conventional methods.

Unexpected Whole-Body Immune Response

Beyond shrinking treated tumors, the therapy triggered a broader immune response throughout the body—something researchers did not anticipate.

This rare effect, where localized treatment leads to systemic results, could represent a major advancement in cancer immunotherapy.

Real Patient Outcomes

In some cases, tumors that were not directly injected also regressed or disappeared entirely.

One patient with advanced melanoma had dozens of metastatic tumors on her leg and foot. After repeated injections into a single tumor on her thigh, all other tumors vanished.

A similar result was seen in a patient with metastatic breast cancer. Even though only a skin tumor was treated, tumors in the liver and lungs also disappeared.

Role of T Cells in Cancer Destruction

Researchers believe the therapy works by activating T cells—specialized immune cells that can identify and destroy cancer throughout the body once activated.

This mechanism allows the immune system to continue targeting cancer cells beyond the initial treatment site.

Future Research and Larger Trials

While the results are highly promising, researchers caution that the study was small and further investigation is needed.

Larger clinical trials are already underway, with nearly 200 patients enrolled, to better evaluate the treatment’s safety, effectiveness, and long-term benefits.